Preclinical research involving individuals with metabolic dysfunction-associated steatohepatitis (MASH) indicated that GLP-1 RAs may decrease hepatic inflammation through processes that are partially unrelated to weight loss. Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.